Instem plc Grant of PDMR Options (8352M)
September 19 2023 - 2:00AM
UK Regulatory
TIDMINS
RNS Number : 8352M
Instem plc
19 September 2023
Instem plc
("Instem" or "the Company")
Grant of PDMR Options
Instem plc (AIM: INS), a leading provider of IT solutions to the
global life sciences market, announces that Phil Reason (Chief
Executive Officer) and Nigel Goldsmith (Chief Financial Officer)
have each been granted options over a total of 47,331 and 43,506
ordinary shares of 10 pence each ("Ordinary Shares") respectively
(the "Awards"). The Awards are split as follows:
PDMR Award Strike No. Awards
Price
Phil Reason Annual Bonus Share Award* Nil 7,331
Phil Reason 2023 LTIP Awards** GBP6.25 40,000
47,331
Nigel Goldsmith Annual Bonus Share Award* Nil 3,506
Nigel Goldsmith 2023 LTIP Awards** GBP6.25 40,000
-----------
43,506
* Bonus Share Awards, granted in lieu of an annual cash bonus
and carry no vesting criteria.
**Annual awards granted under the Company's existing Long Term
Incentive Plan ("LTIPs"). The LTIP Awards are 100% performance
based and will vest equally over three years.
All Awards would vest upon a change of control.
After these grants of Awards, Mr Reason and Mr Goldsmith hold
options over a total of 157,551 and 290,202 Ordinary Shares,
respectively.
For further information, please contact:
Instem plc Via Walbrook
Phil Reason, CEO
Nigel Goldsmith, CFO
Singer Capital Markets (Nominated
Adviser & Broker) +44 (0) 20 7496 3000
Peter Steel
Alex Bond
Oliver Platts
Stifel Nicolaus Europe Limited (Joint
Broker) +44 (0) 20 7710 7600
Ben Maddison
Richard Short
Walbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome
Joe Walker
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Phil Reason
------------------------ --------------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------ --------------------------------------
b) Initial notification Initial
/Amendment
------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
----------------------------------------------------------------
a) Name Instem plc
------------------------ --------------------------------------
b) LEI 213800PILYUFNNROQX68
------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
----------------------------------------------------------------
a) Description 1. Grant of nil cost options in
of the financial lieu of a cash bonus
instrument, type 2. Grant of options pursuant to
of instrument the Company's 2023 LTIP
Identification GB00B3TQCK30
code
b) Nature of the
transaction Grant of options
------------------------ --------------------------------------
c) Price(s) and 1. Price Volume(s)
Volume(s) nil 7,331
----------
2. Price Volume(s)
625p 40,000
----------
------------------------ --------------------------------------
d) Aggregated information
- Aggregated N/A - Single transaction
volume
- Price
e) Date of the 15(th) S eptember 2023
transaction
------------------------ --------------------------------------
f) Place of the Off-market transaction
transaction
------------------------ --------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Nigel Goldsmith
------------------------ --------------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status Chief Financial Officer
------------------------ --------------------------------------
b) Initial notification Initial
/Amendment
------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
----------------------------------------------------------------
a) Name Instem plc
------------------------ --------------------------------------
b) LEI 213800PILYUFNNROQX68
------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
----------------------------------------------------------------
a) Description 1. Grant of nil cost options in
of the financial lieu of a cash bonus
instrument, type 2. Grant of options pursuant to
of instrument the Company's 2023 LTIP
Identification GB00B3TQCK30
code
b) Nature of the
transaction Grant of options
------------------------ --------------------------------------
c) Price(s) and 1. Price Volume(s)
Volume(s) nil 3,506
----------
2. Price Volume(s)
625p 40,000
----------
------------------------ --------------------------------------
d) Aggregated information
- Aggregated N/A - Single transaction
volume
- Price
e) Date of the 15(th) S eptember 2023
transaction
------------------------ --------------------------------------
f) Place of the Off-market transaction
transaction
------------------------ --------------------------------------
About Instem
Instem is a leading provider of IT solutions & services to
the life sciences market delivering compelling solutions for Study
Management, Regulatory Submissions, Clinical Trial Acceleration,
and Informatics-based Insight Generation.
Instem solutions are in use by over 700 customers worldwide,
including all of the largest 25 pharmaceutical companies, enabling
clients to bring life enhancing products to market faster. Instem's
portfolio of software solutions increases client productivity by
automating study-related processes while offering the unique
ability to generate new knowledge through the extraction and
harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug
development value chain, from discovery through to market launch.
Management estimate that over 50% of all drugs on the market have
been through some part of Instem's platform during their
development.
To learn more about Instem solutions and its mission, please visit www.instem.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUWAKROKUKAAR
(END) Dow Jones Newswires
September 19, 2023 02:00 ET (06:00 GMT)
Instem (LSE:INS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Instem (LSE:INS)
Historical Stock Chart
From Jul 2023 to Jul 2024
